{"organizations": [], "uuid": "3b48c54f8f7cc518a87388c6881f19e624b80121", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-aeglea-biotherapeutics-q4-revenue/brief-aeglea-biotherapeutics-q4-revenue-1-5-mln-vs-1-2-mln-idUSASC09RYL", "country": "US", "domain_rank": 408, "title": "BRIEF-Aeglea Biotherapeutics Q4 Revenue $1.5 Mln Vs $1.2 Mln", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-13T13:29:00.000+02:00", "replies_count": 0, "uuid": "3b48c54f8f7cc518a87388c6881f19e624b80121"}, "author": "", "url": "https://www.reuters.com/article/brief-aeglea-biotherapeutics-q4-revenue/brief-aeglea-biotherapeutics-q4-revenue-1-5-mln-vs-1-2-mln-idUSASC09RYL", "ord_in_thread": 0, "title": "BRIEF-Aeglea Biotherapeutics Q4 Revenue $1.5 Mln Vs $1.2 Mln", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-aeglea biotherapeutics", "sentiment": "negative"}, {"name": "thomson", "sentiment": "none"}, {"name": "aeglea bio therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 31 AM / in 7 minutes BRIEF-Aeglea Biotherapeutics Q4 Revenue $1.5 Mln Vs $1.2 Mln Reuters Staff 1 Min Read March 13 (Reuters) - Aeglea Bio Therapeutics Inc: * AEGLEA BIOTHERAPEUTICS PROVIDES KEY CLINICAL DATA UPDATE FROM PHASE 1/2 TRIAL IN ARGINASE 1 DEFICIENCY AND REPORTS Q4 AND FULL YEAR 2017 FINANCIAL RESULTS * Q4 REVENUE VIEW $1.2 MILLION — THOMSON REUTERS I/B/E/S * ‍REPEAT DOSES OF COMPANY’S PEGZILARGINASE PRODUCES MARKED AND SUSTAINED REDUCTIONS IN PLASMA ARGININE LEVELS​ * ‍ACCOMPANYING REDUCTIONS IN OTHER RELATED GUANIDINO COMPOUNDS ALSO SEEN IN STUDY​ * ‍EXPECTS TO REPORT PEDIATRIC AND ADULT REPEAT DOSE DATA IN PATIENTS WITH ARGINASE 1 DEFICIENCY IN Q3 2018​ * AEGLEA BIO - ‍AS OF DEC 31, 2017, HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $50.3 MILLION​ * AEGLEA BIO THERAPEUTICS - BASED ON CURRENT OPERATING PLAN, BELIEVES HAS SUFFICIENT CAPITAL RESOURCES TO FUND ANTICIPATED OPERATIONS THROUGH Q3 2019 * NET LOSS TOTALED $6.5 MILLION AND $5.5 MILLION FOR Q4 OF 2017 AND 2016, RESPECTIVELY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-13T13:29:00.000+02:00", "crawled": "2018-03-13T13:52:27.084+02:00", "highlightTitle": ""}